Compare Mesoblast Limited (MESO) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Block Inc — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Block Inc trades at $77.17 (market cap $45.20B). The key difference: Block Inc is far larger — about 25.8× Mesoblast Limited's market cap, and Block Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Block Inc for 78 Days on average.
| MESO | XYZ | |
|---|---|---|
Market Cap | $1.75B | $45.20B |
Volume | 239,027 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $20.96 | $84.85 |
52-Week Low | $13.19 | $49.04 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $1.83B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Block (XYZ) trades at $77.09, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but faces profitability challenges with a net margin of just 1.43%. Recent developments include expanding Square and Cash App partnerships with Apple and Workday, while pursuing a national trust bank charter to reduce third-party banking costs.
The stock offers 26% upside to the $97.47 consensus target with strong analyst support (77% buy ratings), though high P/E of 134.34 raises valuation concerns. Key risks include declining net income margins, insider selling activity, and competitive fintech pressures. The upcoming Q3 2026 earnings report on November 3rd will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
